SCHEMBL29379994

SCHEMBL29379994

O=c1oc2ccccc2c(O)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.69
NQO1 P15559 8/20 0.67
ALDH1A1 P00352 2/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
LMNA P02545 2/20 0.67
CYP2C9 P11712 2/20 0.67
ABCB11 O95342 1/20 0.67
TP53 P04637 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
TSHR P16473 1/20 0.67
MAPK1 P28482 1/20 0.67
CYP2C19 P33261 1/20 0.67
PDE4D Q08499 1/20 0.67
PCSK7 Q16549 1/20 0.67
GPR35 Q9HC97 1/20 0.67
CA12 O43570 1/20 0.62
CA9 Q16790 1/20 0.62
TOP1 P11387 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7737431 1.00 KDM4E (0.69) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL29872 1.00 KDM4E (0.69) KDM4ENQO1ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL8701572 0.98 KDM4E (0.67) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL28584169 0.86 MEN1 (0.64) KDM4ENQO1ALDH1A1MEN1KMT2A
Dipyridyl SCHEMBL28676053 0.85 ALDH1A1 (0.58) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL5713261 0.83 KDM4E (0.65) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL23727919 0.82 KDM4E (0.62) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL669541 0.82 KDM4E (0.58) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL5459905 0.82 KDM4E (1.00) KDM4ENQO1ALDH1A1MEN1KMT2A
SCHEMBL11693383 0.82 GAA (0.69) KDM4ENQO1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240000950-A1 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2024-01-04 US claimed
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 US claimed
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 US claimed
EP-4192824-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE Cornell University (US) 2023-06-14 EP claimed
EP-4192825-A2 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM Cornell University (US) 2023-06-14 EP claimed
EP-4192504-A2 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM Cornell University (US) 2023-06-14 EP claimed
WO-2022031777-A2 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2022-02-10 WO claimed
WO-2022031774-A2 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2022-02-10 WO claimed
WO-2022031772-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY (US) 2022-02-10 WO claimed
US-20240000950-A1 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2024-01-04 US disclosed
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY 2023-09-14 US disclosed
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 US disclosed
EP-4192825-A2 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM Cornell University (US) 2023-06-14 EP disclosed
EP-4192824-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE Cornell University (US) 2023-06-14 EP disclosed
EP-4192504-A2 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM Cornell University (US) 2023-06-14 EP disclosed
EP-4157811-A1 PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS McMaster University (CA) 2023-04-05 EP disclosed
US-11332707-B2 Endophytic fungus from gingko, metabolite product and use thereof DEZHOU UNIVERSITY (CN) 2022-05-17 US disclosed
WO-2022031777-A2 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2022-02-10 WO disclosed
WO-2022031772-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY (US) 2022-02-10 WO disclosed
WO-2022031774-A2 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2022-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000950-A1 THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM BET1, BRD4, BAZ2A KDM4E 325/4885NQO1 2509/4885ALDH1A1 4266/4885
US-20230285570-A1 THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM XIAP, CUL4A, CUL1 KDM4E 597/4885NQO1 1297/4885ALDH1A1 2592/4885
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE BET1, BRD4, PHKB KDM4E 437/4885NQO1 2725/4885ALDH1A1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.